Publicaciones en las que colabora con RENE RODRIGUEZ GONZALEZ (17)

2024

  1. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

    eBioMedicine, Vol. 102

2023

  1. Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

    Biomedicine and Pharmacotherapy, Vol. 162

  2. Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways

    Biomedicine and Pharmacotherapy, Vol. 161

2020

  1. GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β

    Cell Death and Disease, Vol. 11, Núm. 11

  2. Sox2 expression and transcriptional activity identifies a subpopulation of cancer stem cells in sarcoma with prognostic implications

    Cancers, Vol. 12, Núm. 4

2019

  1. New chondrosarcoma cell lines with preserved stem cell properties to study the genomic drift during in vitro/in vivo growth

    Journal of Clinical Medicine, Vol. 8, Núm. 4

  2. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

  3. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

    Cancers, Vol. 11, Núm. 11

  4. The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas

    International Journal of Cancer, Vol. 145, Núm. 1, pp. 254-266

  5. The novel role of SOX2 as an early predictor of cancer risk in patients with laryngeal precancerous lesions

    Cancers, Vol. 11, Núm. 3

2018

  1. Distinctive expression and amplification of genes at 11q13 in relation to HPV status with impact on survival in head and neck cancer patients

    Journal of Clinical Medicine, Vol. 7, Núm. 12

  2. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway

    Neoplasia (United States), Vol. 20, Núm. 1, pp. 44-56

2017

  1. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models

    Neoplasia (United States), Vol. 19, Núm. 6, pp. 460-470

2016

  1. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma

    Oncotarget, Vol. 7, Núm. 21, pp. 30935-30950

  2. Osteosarcoma: Cells-of-Origin, Cancer stem cells, and targeted therapies

    Stem Cells International, Vol. 2016

2014

  1. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells

    Stem Cells, Vol. 32, Núm. 5, pp. 1136-1148

2013

  1. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation

    Stem Cells, Vol. 31, Núm. 10, pp. 2061-2072